Adding pembrolizumab to Optune and temozolomide for newly diagnosed glioblastoma
Original title: EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large late stage study, but it is still a test and not treatment you can get from your own doctor.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether adding a drug called pembrolizumab to standard Optune and chemotherapy helps people with a new glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary diagnosis.
Who this trial is for. This trial is for people who have just been diagnosed with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, a type of brain tumor. Everyone in it uses Optune, a device that makes Tumor Treating Fields, along with maintenance temozolomide chemotherapy. On top of that, one group also gets pembrolizumab and the other group gets a placebo. Which group a person is in is decided by chance, and the people in the study and their doctors are not told which one it is.
Where it stands. There are no results yet. The main thing the trial is measuring is overall survival, which means how long people live after starting treatment. That answer is not in yet. The study has not reported results.
What this means, and what it doesn't
What it could mean: For now, this tells you that researchers are trying to find out if adding pembrolizumab to Optune and temozolomide helps people live longer. Nobody knows the answer yet. If you were recently diagnosed with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, you could ask your care team whether a study like this is worth looking into for you. Your care team can explain what taking part would involve.
What it doesn't mean: This does not mean pembrolizumab is a proven treatment for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. A trial is a test. It is run because the answer is unknown. Being in a trial is not a guarantee that you will be helped, and you might get the placebo instead. This is not a promise of a cure.
Source: ClinicalTrials.gov, July 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.